Genetic Landscape of Prostate Cancer Conspicuity on Multiparametric Magnetic Resonance Imaging: A Systematic Review and Bioinformatic Analysis
- PMID: 33000006
- PMCID: PMC7497895
- DOI: 10.1016/j.euros.2020.06.006
Genetic Landscape of Prostate Cancer Conspicuity on Multiparametric Magnetic Resonance Imaging: A Systematic Review and Bioinformatic Analysis
Abstract
Context: Multiparametric magnetic resonance imaging (mpMRI) detects most, but not all, clinically significant prostate cancer. The genetic basis of prostate cancer visibility and invisibility on mpMRI remains uncertain.
Objective: To systematically review the literature on differential gene expression between mpMRI-visible and mpMRI-invisible prostate cancer, and to use bioinformatic analysis to identify enriched processes or cellular components in genes validated in more than one study.
Evidence acquisition: We performed a systematic literature search of the Medline, EMBASE, PubMed, and Cochrane databases up to January 2020 in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) statement. The primary endpoint was differential genetic features between mpMRI-visible and mpMRI-invisible tumours. Secondary endpoints were explanatory links between gene function and mpMRI conspicuity, and the prognostic value of differential gene enrichment.
Evidence synthesis: We retrieved 445 articles, of which 32 met the criteria for inclusion. Thematic synthesis from the included studies showed that mpMRI-visible cancer tended towards enrichment of molecular features associated with increased disease aggressivity, including phosphatase and tensin homologue (PTEN) loss and higher genomic classifier scores, such as Oncotype and Decipher. Three of the included studies had accompanying publicly available data suitable for further bioinformatic analysis. An over-representation analysis of these datasets revealed increased expression of genes associated with extracellular matrix components in mpMRI-visible tumours.
Conclusions: Prostate cancer that is visible on mpMRI is generally enriched with molecular features of tumour development and aggressivity, including activation of proliferative signalling, DNA damage, and inflammatory processes. Additionally, there appears to be concordant cellular components and biological processes associated with mpMRI conspicuity, as highlighted by bioinformatic analysis of large genetic datasets.
Patient summary: Prostate cancer that is detected by magnetic resonance imaging (MRI) tends to have genetic features that are associated with more aggressive disease. This suggests that MRI can be used to assess the likelihood of aggressive prostate cancer, based on tumour visibility.
Keywords: Bioinformatic analysis; Genetics; Genomics; Multiparametric magnetic resonance imaging; Prostate cancer; Systematic review.
© 2020 The Author(s).
Figures


Similar articles
-
Genetic landscape of prostate cancer conspicuity on multiparametric MRI: a protocol for a systematic review and bioinformatic analysis.BMJ Open. 2020 Jan 27;10(1):e034611. doi: 10.1136/bmjopen-2019-034611. BMJ Open. 2020. PMID: 31992607 Free PMC article.
-
Histopathological features of prostate cancer conspicuity on multiparametric MRI: protocol for a systematic review and meta-analysis.BMJ Open. 2020 Oct 22;10(10):e039735. doi: 10.1136/bmjopen-2020-039735. BMJ Open. 2020. PMID: 33093035 Free PMC article.
-
Conspicuity of prostate cancer on multiparametric magnetic resonance imaging: A cross-disciplinary translational hypothesis.FASEB J. 2020 Nov;34(11):14150-14159. doi: 10.1096/fj.202001466R. Epub 2020 Sep 13. FASEB J. 2020. PMID: 32920937 Free PMC article.
-
Negative Predictive Value of Multiparametric Magnetic Resonance Imaging in the Detection of Clinically Significant Prostate Cancer in the Prostate Imaging Reporting and Data System Era: A Systematic Review and Meta-analysis.Eur Urol. 2020 Sep;78(3):402-414. doi: 10.1016/j.eururo.2020.03.048. Epub 2020 May 20. Eur Urol. 2020. PMID: 32444265
-
Association Between Multiparametric Magnetic Resonance Imaging of the Prostate and Oncological Outcomes after Primary Treatment for Prostate Cancer: A Systematic Review and Meta-analysis.Eur Urol Oncol. 2021 Aug;4(4):519-528. doi: 10.1016/j.euo.2020.11.008. Epub 2020 Dec 28. Eur Urol Oncol. 2021. PMID: 33384275
Cited by
-
ReIGNITE Radiation Therapy Boost: A Prospective, International Study of Radiation Oncologists' Accuracy in Contouring Prostate Tumors for Focal Radiation Therapy Boost on Conventional Magnetic Resonance Imaging Alone or With Assistance of Restriction Spectrum Imaging.Int J Radiat Oncol Biol Phys. 2023 Dec 1;117(5):1145-1152. doi: 10.1016/j.ijrobp.2023.07.004. Epub 2023 Jul 14. Int J Radiat Oncol Biol Phys. 2023. PMID: 37453559 Free PMC article.
-
Prostate cancer biomarkers and multiparametric MRI: is there a role for both in prostate cancer management?Ther Adv Urol. 2021 Mar 2;13:1756287221997186. doi: 10.1177/1756287221997186. eCollection 2021 Jan-Dec. Ther Adv Urol. 2021. PMID: 33737957 Free PMC article. Review.
-
MRI radiomics predicts progression-free survival in prostate cancer.Front Oncol. 2022 Aug 30;12:974257. doi: 10.3389/fonc.2022.974257. eCollection 2022. Front Oncol. 2022. PMID: 36110963 Free PMC article.
-
Unified model involving genomics, magnetic resonance imaging and prostate-specific antigen density outperforms individual co-variables at predicting biopsy upgrading in patients on active surveillance for low risk prostate cancer.Cancer Rep (Hoboken). 2022 Mar;5(3):e1492. doi: 10.1002/cnr2.1492. Epub 2021 Dec 20. Cancer Rep (Hoboken). 2022. PMID: 34931468 Free PMC article.
-
Histopathologic Features and Transcriptomic Signatures Do Not Solve the Issue of Magnetic Resonance Imaging-Invisible Prostate Cancers: A Matched-Pair Analysis.Prostate. 2025 Mar;85(4):374-384. doi: 10.1002/pros.24838. Epub 2024 Dec 12. Prostate. 2025. PMID: 39665170 Free PMC article.
References
-
- Ahmed H.U., El-Shater Bosaily A., Brown L.C. Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): a paired validating confirmatory study. Lancet. 2017;389:815–822. - PubMed
-
- Bill-Axelson A., Holmberg L., Garmo H. Radical prostatectomy or watchful waiting in prostate cancer—29-year follow-up. N Engl J Med. 2018;379:2319–2329. - PubMed
-
- Fraser M., Sabelnykova V.Y., Yamaguchi T.N. Genomic hallmarks of localized, non-indolent prostate cancer. Nature. 2017;541:359–364. - PubMed
-
- Norris J.M., Simpson B.S., Parry M.A. Genetic correlates of prostate cancer visibility (and invisibility) on multiparametric magnetic resonance imaging: it's time to take stock. BJU Int. 2020;125:340–342. - PubMed
Publication types
Grants and funding
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous